Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$43.20

0.69 (1.62%)

, MYGN

Myriad Genetics

$32.14

-0.15 (-0.46%)

14:38
10/23/19
10/23
14:38
10/23/19
14:38

FDA approves niraparib for HRD-positive advanced ovarian cancer

On October 23, the Food and Drug Administration approved niraparib, or ZEJULA, marketed by GlaxoSmithKline's (GSK) Tesaro, for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency-positive status. The FDA also approved the Myriad (MYGN) myChoice CDx test for determination of tumor HRD status to select patients for niraparib. FDA granted this application priority review. Reference Link

GSK

GlaxoSmithKline

$43.20

0.69 (1.62%)

MYGN

Myriad Genetics

$32.14

-0.15 (-0.46%)

  • 26

    Oct

  • 30

    Oct

  • 06

    Nov

  • 13

    Nov

  • 07

    Dec

GSK GlaxoSmithKline
$43.20

0.69 (1.62%)

09/04/19
COWN
09/04/19
NO CHANGE
Target $48
COWN
Outperform
Pfizer shares remain attractively valued, says Cowen
Cowen analyst Steve Scalia updated his Pfizer (PFE) model following Q2 results, the closing of the Glaxo (GSK) Consumer joint venture, and the announcement that its Upjohn business would be divested and combined with Mylan (MYL). The analyst lowered his estimates to reflect what is left at the company and despite his revision feels the shares remain attractively valued. Scalia reiterated his Outperform rating and $48 price target on Pfizer shares.
10/11/19
CANT
10/11/19
UPGRADE
CANT
Overweight
GlaxoSmithKline upgraded to Buy from Hold at Cantor Fitzgerald
Cantor Fitzgerald analyst Brian White upgraded GlaxoSmithKline to Buy from Hold with a price target of 2,000 pence.
10/11/19
CANT
10/11/19
UPGRADE
CANT
Overweight
Cantor upgrades GSK to Buy on reinvigoration of cancer franchise
Cantor Fitzgerald analyst Brian White upgraded GlaxoSmithKline to Buy from Hold with a price target of 2000 pence, up from 1450 pence. The Novartis transactions bolstered GSK's Vaccines and Consumer businesses at the expense of Pharma, while recent events have served to continue the theme while reinvigorating the cancer franchise, White tells investors in a research note. The analyst believes GSK has access to differentiated oncology products, "which promise to form a cornerstone for future franchise building." Further, consummation of the Consumer business should drive greater profitability "but Pharma has a narrow window to build a sustainable late stage pipeline," he adds.
10/16/19
NWST
10/16/19
UPGRADE
NWST
Neutral
GlaxoSmithKline upgraded to Hold from Reduce at New Street
MYGN Myriad Genetics
$32.14

-0.15 (-0.46%)

09/24/19
PIPR
09/24/19
NO CHANGE
Target $40
PIPR
Neutral
Myriad competitor allowed to keep pharmacogenomic stoplight, says Piper Jaffray
Myriad Genetics competitor Genomind resumed including specific drug recommendations in physician reports following interaction with FDA, but only for physician clients as patient reports only include the genotype information, Piper Jaffray analyst William Quirk tells investors in a research note. While there remains considerable uncertainty in the pharmacogenomics landscape, the recent move by Genomind is a positive read through for Myriad's GeneSight, says the analyst. He points out that several industry groups are lobbying the FDA to reverse their recent action against pharmacogenomic Clinical Laboratory Improvement Amendments-certified labs. This suggests the GeneSight psychotropic test report could remain on market as is, contends Quirk. He keeps a Neutral rating on shares of Myriad Genetics.
09/25/19
LEHM
09/25/19
NO CHANGE
Target $22
LEHM
Underweight
Barclays, following 'regulatory breadcrumbs,' stays Underweight on Myriad
The most important debate for shares of Myriad Genetics remains potential regulatory action for GeneSight, Barclays analyst Jack Meehan tells investors in a research note. The analyst believes recent "regulatory breadcrumbs" confirm the risks inherent in his Underweight thesis on Myriad shares. The most recent important update was a letter submitted by the American Clinical Laboratory Association to the FDA on September 18 saying that the ACLA is "Deeply Concerned by FDA Actions on Pharmacogenetic Testing," says Meehan. If the lab industry were having positive FDA dialogue, there would have been no need to publish a formal four-page letter raising concerns about the regulatory review taking place, contends the analyst. He believes potential premarket approval application review of the test would raise further regulatory risk for GeneSight.
09/26/19
BOFA
09/26/19
DOWNGRADE
BOFA
Underperform
Myriad Genetics downgraded to Underperform from Neutral at BofA/Merrill
09/26/19
BOFA
09/26/19
UPGRADE
BOFA
Buy
Bruker, PerkinElmer, Personalis upgraded to Buy at BofA/Merrill
BofA/Merrill analyst Derik de Bruin upgraded Bruker (BRKR), PerkinElmer (PKI), and Personalis (PSNL) to Buy from Neutral as part of his broader research note into Life Sciences & Diagnostic Tools. The analyst notes that the recent market volatility has sent many of the names in the sector "sharply lower", making their valuations more attractive. de Bruin is also positive on Bruker's new product portfolio and margin expansion opportunity. As part of the research note, the analyst cuts Myriad Genetics (MYGN) to Underperform from Neutral and lowers his price target on the shares to $28 from $30 after a bounce in its stock price and given his concern with its mixed execution.

TODAY'S FREE FLY STORIES

CMCSK

Comcast

$0.00

(0.00%)

, CMCSA

Comcast

$44.54

-0.93 (-2.05%)

18:02
11/15/19
11/15
18:02
11/15/19
18:02
Hot Stocks
Viacom extends cable deal for 'The Office' through 2025 »

Viacom (VIA) announced…

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

VIAB

Viacom

$23.07

0.59 (2.62%)

VIA

Viacom

$26.59

1.28 (5.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CWK

Cushman & Wakefield

$19.10

0.1 (0.53%)

17:48
11/15/19
11/15
17:48
11/15/19
17:48
Hot Stocks
Cushman & Wakefield CEO sells 84.6K share of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LMT

Lockheed Martin

$393.52

3.305 (0.85%)

17:39
11/15/19
11/15
17:39
11/15/19
17:39
Hot Stocks
Lockheed Martin awarded maximum $3.33B Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESCA

Escalade

$10.90

-0.09 (-0.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Escalade CEO Fetherman to retire »

Escalade announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.96

0.1 (0.78%)

, ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Eldorado, Caesars stockholders approve Eldorado acquisition of Caesars »

Eldorado Resorts (ERI)…

CZR

Caesars

$12.96

0.1 (0.78%)

ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EGRX

Eagle Pharmaceuticals

$57.24

0.55 (0.97%)

17:15
11/15/19
11/15
17:15
11/15/19
17:15
Syndicate
Breaking Syndicate news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$60.82

0.84 (1.40%)

17:11
11/15/19
11/15
17:11
11/15/19
17:11
Hot Stocks
Fabrinet President Gill sells 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TEUM

Pareteum

$0.38

-0.0209 (-5.21%)

17:05
11/15/19
11/15
17:05
11/15/19
17:05
Hot Stocks
Pareteum receives noncompliance notice from Nasdaq »

Pareteum announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

Hexo

$1.78

-0.1 (-5.32%)

17:00
11/15/19
11/15
17:00
11/15/19
17:00
Hot Stocks
Hexo was cannabis was being grown in unlicensed space at Niagara site »

HEXO Corp provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

, CELG

Celgene

$110.02

-0.01 (-0.01%)

16:57
11/15/19
11/15
16:57
11/15/19
16:57
Hot Stocks
Bristol-Myers gets FTC clearance for Celgene acquisition »

Bristol-Myers Squibb…

AMGN

Amgen

$220.84

2.29 (1.05%)

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

RAVE

Rave Restaurant

$1.44

-0.79 (-35.43%)

16:47
11/15/19
11/15
16:47
11/15/19
16:47
Hot Stocks
BBRC Asset Management reports 6.6% passive stake in Rave Restaurant »

BBRC Asset Management …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHAP

Chaparral Energy

$0.89

-0.0521 (-5.52%)

16:46
11/15/19
11/15
16:46
11/15/19
16:46
Hot Stocks
Chaparral Energy receives continued listing standard notice from NYSE »

Chaparral Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

CI

Cigna

$196.08

6.41 (3.38%)

, CNC

Centene

$57.57

2.91 (5.32%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks closed out the…

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

NVDA

Nvidia

$204.12

-5.76 (-2.74%)

AMZN

Amazon.com

$1,739.33

-15.38 (-0.88%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

UAA

Under Armour

$17.78

0.65 (3.79%)

UA

Under Armour

$15.97

0.41 (2.64%)

AMRN

Amarin

$23.99

2.5 (11.63%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

GOOG

Alphabet

$1,334.01

21.82 (1.66%)

GOOGL

Alphabet Class A

$1,333.33

23.54 (1.80%)

ORCL

Oracle

$56.43

0.33 (0.59%)

RH

RH

$188.73

13.535 (7.73%)

QGEN

Qiagen

$40.56

3.255 (8.73%)

FTCH

Farfetch

$9.66

2.17 (28.97%)

THC

Tenet

$30.55

1.08 (3.66%)

TORC

resTORbio

$1.10

-6.83 (-86.13%)

ACB

Aurora Cannabis

$2.72

-0.57 (-17.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 28

    Dec

  • 06

    Jan

  • 21

    Jan

  • 06

    Feb

NYT

New York Times

$31.60

0.44 (1.41%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
New York Times CEO sells 66,000 class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WEX

Wex

$200.52

4.61 (2.35%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
Wex director Morris sells 3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBLI

Cleveland BioLabs

$0.59

-0.0444 (-6.97%)

16:39
11/15/19
11/15
16:39
11/15/19
16:39
Hot Stocks
Cleveland BioLabs CEO resigns effective December 13th »

In a regulatory 8-K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGC

LogicBio Therapeutics

$9.29

-0.04 (-0.43%)

16:38
11/15/19
11/15
16:38
11/15/19
16:38
Syndicate
Breaking Syndicate news story on LogicBio Therapeutics »

LogicBio Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTBI

HomeTrust

$25.99

-0.31 (-1.18%)

16:38
11/15/19
11/15
16:38
11/15/19
16:38
Hot Stocks
HomeTrust raises quarterly dividend 17% to 7c per share »

HomeTrust Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

FR

First Industrial Realty

$42.05

-0.03 (-0.07%)

16:36
11/15/19
11/15
16:36
11/15/19
16:36
Hot Stocks
First Industrial Realty director sells 12K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSI

United Bankshares

$39.51

-0.19 (-0.48%)

16:31
11/15/19
11/15
16:31
11/15/19
16:31
Hot Stocks
United Bankshares declares Q4 dividend of 35c per share »

United Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
11/15/19
11/15
16:30
11/15/19
16:30
Options
Preliminary option volume of 24.0M today »

Preliminary option volume…

16:25
11/15/19
11/15
16:25
11/15/19
16:25
Conference/Events
Federal Reserve Bank of San Francisco participates in a discussion »

San Francisco Federal…

GNLN

Greenlane

$3.36

-0.05 (-1.47%)

16:23
11/15/19
11/15
16:23
11/15/19
16:23
Hot Stocks
Greenlane CEO buys 56.4K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.